Biocom - Life Sciences Association of California
Close
Call
Profile
San Diego  |   Los Angeles  |   Washington, DC  |   Tokyo
cONTENT bLOCK
Left
Left
https://www.biocom.org/servlet/servlet.ImageServer?id=0152A000006ppaZQAQ&oid=00DA0000000Kz7JMAS  

Biocom CFO Series: Secrets of Alternative Funding

 
When:
Wednesday, June 28 2017 - Wednesday, June 28 2017
7:00 AM - 9:00 AM

Add to Calendar America/Los_Angeles Biocom CFO Series: Secrets of Alternative Funding ​Success in Life Science startups is a function of breakthrough research and creative funding.  While most Life Science startups flock to Venture Capitalists, only 1/100 typically get funded.  So what are the alternative funding mechanisms out there?  Biocom false MM/DD/YYYY

Where:
The Alexandria
10996 Torreyana Road
San Diego, CA 92121
Registration Deadline:
Tuesday, June 27 2017
12:00 PM
Register


Secrets of Alternative Funding: 
More Options and More Money for Life Sciences Than You Knew

Success in Life Science startups is a function of breakthrough research and creative funding.  While most Life Science startups flock to Venture Capitalists, only 1/100 typically get funded.  So what are the alternative funding mechanisms out there?  We invite you to join the Biocom CFO Breakfast Series on Wednesday, June 28th to learn from your other business colleagues about how they got their businesses off the ground with almost no funding from Venture Capitalists or traditional investment partners.

Leslie Schulze, CFO of Origami Therapeutics will share how she has played a significant role in helping companies obtain equity and non-dilutive funding, including government grants and contracts (with one award up to $90M from BARDA).  Additionally, Craig Misrach Founder and 8+ year CEO of Freedom Meditech, will share how he helped lead the company in receiving over 17MM in funding since inception, with a significant portion coming from Super Angel Investors (not Angel organizations) both domestically and abroad.​ Sabrina Martucci Johnson, Founder and CEO of Daré Bioscience, will share how Daré entered a stock purchase agreement as a transaction to create a NASDAQ-listed company and access capital.

Kicking off the panel discussion will be a State of the Industry Update led by Ernst & Young. 


Moderator:
Albert Oaten, Vice President of Market Development and Co-Founder, SecureDocs

Panelists: 
Sabrina Johnson, Founder & CEO, Dare Bioscience

Leslie Schulze, CFO, Origami Therapeutics

Craig Misrach, Investment Advisor, Founding CEO, Board Member


Agenda: 
7:00 am: Networking
7:45 am: State of the Industry Update led by Ernst & Young
8:00 am: Event Panel & Breakfast
9:00 am: Event Concludes

Learn more about the Biocom CFO Series here

*Please note: This event is intended for CFOs and/or Senior Executives of Finance only. In addition, this event is only open to C-level industry companies and closed to all service providers of Biocom, with the exception of our Premium Members. Only one person from our Premium Provider companies is able to attend and they must be a C-Level Executive. A service provider is a company that does not directly work with a substance that needs approval by the FDA and/or does business-to-business sales. They provide a service to the biotechnology and pharmaceutical industry and includes, but is not limited to, law firms, banks, laboratory equipment suppliers, consulting firms, or IT services.

Planner

Ashleigh Farver
 

Sponsored By: